Status:

ENROLLING_BY_INVITATION

Pulmonary Hypertension Inspiratory Training

Lead Sponsor:

University of Arizona

Conditions:

Pulmonary Hypertension

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study is examining the effects of six weeks of inspiratory muscle strength training (IMST) on outcomes related to pulmonary hypertension. This study leverages previous cardiopulmonary exercise te...

Detailed Description

PH is a condition characterized by abnormally high blood pressure in the lungs (i.e., pulmonary arterial pressure), which impacts heart function and reduces exercise tolerance. This study will assess ...

Eligibility Criteria

Inclusion

  • Diagnosed with PH defined by clinical guideline criteria
  • Must already be scheduled for a clinical assessment of their PH within 8 weeks of enrolling in the study.
  • Must have undergone an assessment of their PH in the last 18 months with no major changes in PH management or medication within that period.

Exclusion

  • Current smoker or have smoked in the last 10 years
  • Unable or unwilling to undergo routine functional testing of their PH (i.e., 6-minute walk distance).
  • Presence of significant cardiovascular or respiratory conditions other than PH, including but not limited to:
  • Chronic obstructive pulmonary disease
  • Severe asthma
  • Severe ischemic heart disease
  • Left-sided heart failure
  • History of a major cardiovascular event, such as a myocardial infarction or stroke, within the last 6 months
  • Individuals with an implanted pacemaker or other significant cardiac devices
  • History of neurological, respiratory, head and neck, or thoracic surgeries, or conditions such as a collapsed lung or perforated eardrum
  • Pregnant individuals or those actively trying to become pregnant
  • Individuals with any of the following: chronic laryngitis, chronic bronchitis, emphysema, pneumonia, tuberculosis, chronic cough, extremely high blood pressure (\>170/100), neurological problems, scoliosis, organ transplants, HIV or other immunocompromising conditions, or autoimmune disease.

Key Trial Info

Start Date :

October 25 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2026

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT06931886

Start Date

October 25 2025

End Date

October 1 2026

Last Update

December 17 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Arizona

Tucson, Arizona, United States, 85711